Outcome of Multiple Myeloma Associated With Autoimmune Hemolytic Anemia: Cross-sectional Study
| Registry | NCT07354191 |
|---|---|
| Status | Completed |
| Phase | Not applicable |
| Study type | Interventional; na, single group, masking: none, screening |
| Enrollment | 66 (Actual) |
| Sponsor | New Valley University (Other) |
| Conditions | Multiple Myeloma |
| Interventions | direct antiglobulin test (DAT), Indirect antiglobulin test (IAT) (Diagnostic test) |
| Dates | start 2023-01-15, primary completion 2025-11-05, completion 2025-11-06, first posted 2026-01-21, last updated 2026-01-21 |
| Locations | 1 site in Egypt |
Related Papers Related Patents Related Grants Related Experts
All trials for Multiple Myeloma All trials of direct antiglobulin test (DAT) All trials of Indirect antiglobulin test (IAT)
Autoimmune hemolytic anemia (AIHA) is a highly heterogeneous disease due to increased destruction of autologous erythrocytes by autoantibodies with or without complement involvement. Other pathogenic mechanisms include hyper-activation of cellular immune effectors, cytokine dysregulation, and ineffective marrow compensation.
AIHAs may be primary or associated with lymphoproliferative and autoimmune diseases, infections, immunodeficiencies, solid tumors, transplants, and drugs. The direct antiglobulin test is the cornerstone of diagnosis, allowing the distinction into warm forms (wAIHA), cold agglutinin disease (CAD), and other more rare forms. Multiple myeloma (MM), on the other hand, is characterized by a clonal expansion of plasma cells in bone marrow, causing bone tissue destruction, renal failure and hematopoietic suppression. Although the association of MM and anemia is common, AIHA as the anemic manifestation of MM is rare. This prospective study will be conducted to detect the presence of AIHA in MM patients and its impact on clinical presentation and outcome of the disease.
| Arm | Type | Interventions | Description |
|---|---|---|---|
| MM patients | Experimental | Diagnostic Test: direct antiglobulin test (DAT); Diagnostic Test: Indirect antiglobulin test (IAT) | the prevalence of AIHA in MM patients and determine its impact on clinical presentation and outcome of the disease |
Sex: All, ages: 18 Years to any
Inclusion Criteria: * Clinical diagnosis of multiple myeloma Exclusion Criteria: * No
| Facility | City | Country | Status |
|---|---|---|---|
| Assiut University | Asyut | Egypt |